Prader-Willi Syndrome Financial Planning: Hyperphagia, SNT Food-Control Strategy, and Specialized Housing

Prader-Willi syndrome presents a financial planning problem that no other disability creates in quite the same way: the beneficiary's most dangerous threat is food. Hyperphagia — the neurological inability to feel satiety — means an adult with PWS will seek food relentlessly, and unrestricted access to food or cash can cause life-threatening overeating. This isn't a preference or a behavioral failure; it is the defining medical characteristic of PWS. A well-structured financial plan must account for this reality at every level: the Special Needs Trust cannot distribute cash; housing must be a food-secured environment; ABLE accounts require careful design to prevent misuse; and life insurance sizing must account for a planning horizon that has lengthened dramatically as food management has improved. This guide covers the unique financial planning considerations for PWS families — from SNT structure to specialized housing costs to the emerging GLP-1 treatment landscape — for parents and siblings navigating a lifetime plan for a loved one with PWS.

Who this affects: PWS prevalence and the planning population

Prader-Willi syndrome affects approximately 1 in 15,000 live births, with estimates ranging from 1 in 10,000 to 1 in 30,000 depending on the study population and diagnostic methodology.¹ Approximately 20,000 to 40,000 individuals in the United States have PWS. PWS is caused by the loss of normally active genes in a specific region of chromosome 15 — either by deletion of the paternal copy, maternal uniparental disomy (both chromosome 15s from the mother), or an imprinting defect. It is not inherited in the traditional sense; most cases arise as spontaneous events.

The planning population for this guide is primarily parents of children with PWS who are in the process of establishing a Special Needs Trust, updating estate plans, or navigating the transition to adult services — as well as adult siblings who may be approaching the trustee or guardian role as parents age. Because PWS involves complex behavioral management, the transition from parent-managed care to a formal trustee and residential structure is one of the highest-stakes financial planning milestones in any PWS family's timeline.

Hyperphagia: the financial planning constraint that shapes everything else

Hyperphagia — the insatiable drive to eat caused by a hypothalamic dysfunction in PWS — is not simply excessive hunger. It is a neurological state in which the satiety signal does not function: individuals with PWS do not feel full regardless of how much they eat. Left unsupervised with food access, a PWS adult will eat to the point of gastric rupture or choking — both of which have caused preventable deaths in this population.²

For financial planning purposes, hyperphagia has three direct implications:

• Cash distributions are dangerous. A trustee who distributes cash to a PWS beneficiary for "personal needs" is creating a food-access risk. The beneficiary may immediately use funds to purchase food from a vending machine, convenience store, or restaurant. SNT distribution language for PWS must substitute vendor-direct payments for all cash distributions.
• Housing selection is non-negotiable. Standard group homes, supported living arrangements, and family home settings are only appropriate if food security protocols are in place: locked pantries and refrigerators, controlled portions, no unsupervised kitchen access, and staff trained in PWS-specific behavioral management. Specialized PWS group homes provide this structure and cost significantly more than standard DD residential settings.
• ABLE accounts require careful management design. ABLE accounts give the account holder direct control over funds — by design. For most special needs populations, this autonomy is beneficial. For many PWS adults, unrestricted ABLE debit card access creates the same risk as cash. The ABLE account should either be managed by an authorized individual (who controls distributions) or structured with a daily spending cap and monitoring, rather than giving the PWS adult independent account control.

SSA qualification: Blue Book pathways for PWS adults

PWS affects cognitive development, adaptive behavior, and psychiatric/behavioral functioning across a spectrum. Most adults with PWS qualify for SSI and SSDI under one or more SSA Blue Book listings, but the applicable pathway depends on the individual's specific profile.³

Listing 12.05: Intellectual Disorder

Many adults with PWS have IQ scores in the borderline-to-mild intellectual disability range (typically 60–80, though the range is wide). Listing 12.05 qualification requires:

• A full-scale IQ score of 70 or below on a standardized intelligence test; OR a full-scale IQ score of 71–75 AND a marked limitation in one of four areas of mental functioning (understanding/applying information, interacting with others, concentrating/persisting/maintaining pace, or adapting/managing oneself); AND
• Evidence that the intellectual disorder began before age 22 (PWS is congenital — this is automatic)

For PWS adults with IQ in the 70–85 range who may not meet the 12.05 intellectual disorder threshold on test scores alone, the behavioral dysregulation characteristic of PWS — including emotional outbursts, severe obsessive-compulsive behaviors, skin picking (excoriation disorder, present in 80–90% of PWS adults), and extreme food-seeking behaviors — supports a marked limitation in adaptive functioning that, combined with borderline IQ, can satisfy 12.05.

Listing 12.11: Neurodevelopmental Disorders

Listing 12.11 covers neurodevelopmental disorders that manifest during the developmental period, including conditions characterized by deficits in cognitive, motor, language, or social domains. PWS qualifies as a neurodevelopmental disorder — its hypothalamic dysfunction causes hyperphagia, hypogonadism, growth hormone deficiency, and behavioral dysregulation, all originating from the same genetic deletion during development. Qualification under 12.11 requires:

• One or more of: significant deficits in intellectual functions, significant deficits in oral expression/listening comprehension/written expression/math reasoning, or impairments in focusing attention, impulse control, or social interaction consistent with the disorder; AND
• Extreme limitation in one area of mental functioning OR marked limitation in two areas

For PWS adults with IQ in the normal-to-borderline range but with severe behavioral dysregulation, impulsivity, and social functioning deficits, 12.11 may provide the primary pathway when 12.05 is not available.

Medical-vocational allowance for adults who don't meet a listing

A small percentage of PWS adults — typically those with higher IQ and milder behavioral profiles — may not meet a Blue Book listing based on test scores alone. SSA's medical-vocational grid analysis considers the individual's residual functional capacity (RFC): their ability to sustain work activity given the combined functional limitations of PWS, including behavioral dysregulation, obsessive-compulsive behaviors, difficulty following multi-step instructions, and the need for constant supervision. For PWS adults who require structured food-secured environments, a medical-vocational analysis will generally find that the behavioral management requirements are incompatible with competitive employment without substantial accommodation.

SSA Compassionate Allowances

PWS is not currently on SSA's Compassionate Allowances list as of 2026, meaning applications proceed through standard review rather than the 10-day fast-track. Standard processing typically takes 3–6 months for initial applications; appeals can extend this timeline significantly. Parents applying for adult children with PWS who are transitioning off parental deeming rules should file SSI applications 3 months before the child's 18th birthday to establish the earliest possible benefit date — see the Age-18 Transition Planning guide for the full SSI deeming shift timeline.

SNT structure and distribution rules for PWS

A Special Needs Trust for a PWS beneficiary is structurally similar to an SNT for any beneficiary — it preserves SSI and Medicaid eligibility by holding assets outside the $2,000 SSI resource limit and making supplemental distributions that do not replace government benefits. But PWS-specific distribution language is essential.

The cash prohibition and vendor-direct requirement

Every SNT drafted for a PWS beneficiary should include explicit language along the following lines (to be customized by an attorney experienced in SNT drafting and PWS):

• The trustee shall not distribute cash or cash equivalents — including gift cards with no spending restrictions — directly to the beneficiary.
• All payments for beneficiary expenses shall be made directly to service providers, vendors, and professionals — not to the beneficiary.
• No food or food-purchase credits shall be made available to the beneficiary without the express supervision and approval of the beneficiary's residential provider or designated care coordinator.
• The beneficiary shall not have signatory authority over any account, debit card, or financial instrument held in the trust.

Standard SNT language — which often gives the beneficiary limited cash distributions for personal spending — is not appropriate for PWS. An attorney who has not drafted SNTs for hyperphagia populations may need to be directed to incorporate this language explicitly.

ISM and the 2024 food rule change

Under a 2024 SSA rule change (Emergency Message EM-24048, effective September 30, 2024), food payments no longer count as In-Kind Support and Maintenance (ISM) for SSI calculation purposes.⁴ Previously, if an SNT paid for food directly, it could reduce the beneficiary's SSI payment by up to one-third of the Federal Benefit Rate (approximately $331/month in 2026). Under the new rule, food payments from an SNT do not reduce SSI.

For PWS families, this change removes a benefit-calculation concern that previously complicated decisions about structured meal programs. The SNT can now fund specialized meal delivery, nutrition counseling, supervised grocery purchasing through a residential provider, and food management supplies (portion control equipment, food scales, supervised food logs) without triggering an SSI reduction. The medical necessity of food control remains unchanged — this rule change removes a financial planning obstacle, not a clinical one.

Safe and PWS-appropriate distribution categories

Categories of SNT distributions appropriate for PWS beneficiaries (to be confirmed by an attorney):

• Residential housing costs above what Medicaid or HCBS waiver covers (paid directly to the residential provider)
• Supervised nutrition programs, dietitian services, and meal delivery through licensed providers (paid directly to providers)
• ABA therapy, behavioral support services, and PWS-specialized therapists (paid directly to providers)
• Transportation to medical appointments, social and recreational activities, and vocational programs (paid to transportation providers)
• Medical equipment, adaptive technology, and health-related devices (paid directly to vendors)
• Personal care items, clothing, and household goods — purchased by the trustee or residential staff on the beneficiary's behalf, not via cash distribution
• Recreational activities, vacations, and social participation — pre-arranged and paid directly, with food-management plans in place for any outing involving food
• GLP-1 medications or other emerging PWS treatments not covered by Medicaid (paid directly to pharmacy)

Specialized housing costs: why PWS residential care costs more

For PWS adults who cannot safely live in the family home — which becomes most families' reality as parents age — residential placement in a specialized, food-secured environment is the primary long-term housing solution. Specialized PWS group homes differ from standard DD group homes in several important respects:

• Locked food storage: All refrigerators, pantries, and food storage must be secured with locks accessible only to staff. Standard DD homes do not have this infrastructure; PWS-specific homes do.
• Calorie-controlled kitchen protocols: Meals are prepared according to individually prescribed caloric budgets, typically 1,000–1,400 calories/day for adults with PWS (substantially below typical adult needs due to PWS's reduced caloric requirements from lower muscle mass). This requires trained kitchen staff and documentation.
• Higher staff ratios during meals and transition times: The highest-risk periods for food seeking are meals, post-meal periods, and any community outing near food. Staff trained in PWS behavioral management are required during these periods.
• Staff continuity: Unfamiliar staff who are unaware of PWS food rules are a significant risk. PWS homes typically have lower staff turnover and stricter training requirements than general DD homes.

Annual costs for specialized PWS residential placement typically range from $60,000 to $120,000 or more per year, compared to $40,000 to $80,000 per year for standard DD group homes and $30,000 to $45,000 for supported living with standard services.¹ In high-cost-of-living states, PWS residential costs at the upper end can exceed $120,000/year. HCBS waiver funding covers a substantial portion of this cost for eligible individuals — but waiver rates are set by the state and may not cover the full cost of specialized PWS settings, leaving a gap that the SNT must fund.

SNT sizing implications

When sizing a third-party SNT for a PWS beneficiary, families must model two scenarios:

• HCBS waiver scenario: If the beneficiary secures an HCBS DD waiver slot, the waiver funds the vast majority of residential, day program, and personal care costs. The SNT is sized to cover the gap between waiver rates and actual PWS-specialized costs, plus supplemental quality-of-life expenses. SNT reserve in this scenario: typically $500,000–$1.5M depending on the gap and supplemental needs.
• Private-pay residential scenario: If HCBS waiver is unavailable (national waitlists for DD waiver average 5–15 years — see the HCBS Medicaid Waiver guide), the SNT must fund private residential costs directly. At $80,000–$120,000/year for specialized PWS housing over a 35–50 year horizon, the funding need is substantial. SNT reserve in this scenario: typically $2M–$5M or more, depending on life expectancy, inflation assumptions, and whether family members can serve in a co-residential role during any period.

Use the Lifetime Care Cost Projection Calculator to model both scenarios. Select the group home care setting ($45,000–$60,000/year as a conservative base for a PWS-specialized setting) and adjust upward based on current market rates in your state. Then use the SNT Funding Calculator to determine how much life insurance or other funding is needed to close the gap between projected waiver coverage and estimated total residential cost.

HCBS Medicaid waiver: urgency for PWS families

HCBS (Home and Community Based Services) Medicaid waivers fund the residential, day program, and personal care services that allow adults with developmental disabilities to live in the community rather than in institutional settings. For PWS families, an HCBS DD waiver slot is transformative: it can reduce the annual out-of-pocket residential cost from $80,000–$120,000/year to $10,000–$30,000/year in gap costs funded by the SNT.

The problem is waitlists. Nationally, more than 607,000 individuals with ID/DD are on HCBS waiver waitlists, with average wait times of 5–15 years in most states. In some states (Texas, Florida, Tennessee), waitlists exceed 10–15 years for new applicants.⁵

Apply for the HCBS DD waiver as soon as your child with PWS reaches eligibility — typically age 3 or the point of formal PWS diagnosis. The waitlist position is established at the date of application, not the date care is needed. A family that applies when their child is 5 and faces a 12-year waitlist will have their position when the child is 17 — still ahead of the adult transition. A family that waits until their child is 16 to apply may face the same 12-year wait, with their child reaching the top of the list at 28 — years into adulthood with no waiver coverage in the interim.

Most states offer expedited waiver processing for individuals who are medically fragile, at risk of institutionalization, or experiencing a care crisis. PWS families who experience a residential breakdown (a group home unable to manage hyperphagia behaviors, or a family home situation that becomes unsafe) may be able to request expedited placement. Document all behavioral incidents, hospitalizations for food-related emergencies, and care failures — this documentation supports expedited status.

Growth hormone therapy: cost planning across the lifespan

Growth hormone (GH) deficiency is a universal feature of PWS — it is one of the few conditions for which GH therapy in childhood is FDA-approved and routinely covered by insurance.² Childhood GH therapy (Genotropin, Norditropin, Humatrope, and others) costs approximately $10,000–$50,000 per year depending on dosage and formulation. Pediatric GH therapy for PWS is well-established as covered by commercial insurance and Medicaid when properly documented, as it treats the growth failure, body composition abnormality, and metabolic effects of PWS.

The financial planning issue arises at adulthood. Adult GH therapy for PWS is not FDA-approved for growth (the indication that drives pediatric coverage) but may be prescribed off-label for PWS adults for metabolic benefits. Insurance coverage is inconsistent and often requires annual prior authorization with documentation of continued benefit. Families transitioning an adult with PWS off of pediatric GH therapy coverage should:

• Work with an endocrinologist to document adult GH deficiency via stimulation testing, establishing a medical basis for continued treatment
• Confirm coverage under the adult's Medicaid plan or commercial coverage before the pediatric coverage ends
• Budget for potential coverage gaps — a year without GH therapy can result in measurable body composition deterioration and functional decline
• Include adult GH therapy costs (potentially $10,000–$30,000/year) in SNT distribution planning if coverage is uncertain

GLP-1 agonists and the emerging hyperphagia treatment landscape

GLP-1 receptor agonists — including semaglutide (Ozempic/Wegovy) and liraglutide — have shown promising signals for reducing hyperphagia in early PWS clinical trials as of 2024–2025.² Unlike the hypothalamic satiety circuits that are dysfunctional in PWS, GLP-1 receptors act on a different pathway and may modulate food drive. Several trials are ongoing.

GLP-1 agents are not FDA-approved for hyperphagia management in PWS as of 2026, meaning coverage by Medicaid or commercial insurance for this specific indication is inconsistent and requires prior authorization or off-label prescribing. List price for semaglutide injections runs approximately $900–$1,400/month without insurance. For PWS adults on SSI/Medicaid, Medicaid coverage varies by state and indication; some state Medicaid programs cover GLP-1 agents for obesity treatment, which would apply to many PWS adults.

From a financial planning standpoint:

• Do not yet underwrite the SNT assuming GLP-1 treatment will eliminate hyperphagia management costs — the evidence is promising but not conclusive.
• Do build in a medical cost reserve in the SNT for emerging treatments — whether GLP-1, oxytocin therapy, or other pharmacological interventions — that Medicaid may not cover promptly.
• If a PWS adult is successfully stabilized on a GLP-1 agent and hyperphagia is meaningfully reduced, revisit the housing cost assumptions. A PWS adult with managed hyperphagia may be appropriate for a less intensive residential setting at lower cost.

ABLE accounts: cautions for PWS families

ABLE accounts allow eligible individuals to save beyond the SSI $2,000 resource limit without losing benefits — up to $100,000 in ABLE savings does not count toward the SSI resource test. Key 2026 ABLE rules:⁶

• Age eligibility: disability onset before age 46 (PWS is congenital — all PWS individuals qualify)
• Annual contribution limit: $20,000 from all sources
• ABLE-to-Work additional contribution: $15,650 from earned income for PWS adults who work
• SSI protection: balances up to $100,000 don't count toward the resource limit

However, ABLE accounts are designed around the account holder having meaningful autonomy over funds — the account holder typically has their own debit card for qualified disability expenses. For a PWS adult with significant hyperphagia and food-seeking behaviors, an ABLE debit card with independent spending authority creates a food-access risk: the beneficiary can use the card to purchase food at any point.

The mitigation strategies available for ABLE accounts and PWS:

• Authorized individual management: ABLE accounts may be managed by an authorized individual (a parent, guardian, or other designated person) who controls distributions on behalf of the account holder. For PWS adults under guardianship or with a representative payee, the authorized individual mechanism provides appropriate oversight. Confirm with your state's ABLE plan that the authorized individual has exclusive transaction authority.
• No independent debit card for the beneficiary: Ensure the ABLE account structure does not provide the PWS adult with an independent debit card unless there is appropriate supervision and spending controls in place.
• Use the ABLE for specific expenses only: Structure ABLE account use around transportation, medical copays paid by providers, and other non-food qualifying expenses where vendor-direct payment is practical.

For PWS adults with severe hyperphagia, the SNT (with vendor-direct distribution requirements) may be a safer vehicle for most assets than an ABLE account with individual access. Discuss with a special needs financial planner which vehicle is appropriate for the specific individual's functional profile.

Life insurance and the extended planning horizon

Historically, life expectancy for individuals with PWS was substantially shorter than general population, primarily due to hyperphagia-related complications and obesity. Modern food management has changed this profile significantly: adults with PWS living in structured, food-secured environments now commonly live into their 50s and 60s, and the trajectory continues to improve as specialized residential settings become more widespread.¹

For parents funding a third-party SNT primarily through life insurance, this extended horizon has two implications:

• Policy sizing: A survivorship (second-to-die) life insurance policy sized on a 25–35 year planning horizon may be insufficient if the adult child with PWS now has a life expectancy of 40–50+ years post-parental death. Update the policy sizing analysis with current actuarial assumptions for PWS, not outdated population statistics.
• Insurer underwriting: Some life insurance underwriters may apply outdated PWS mortality tables that assume shorter life expectancy, which can paradoxically make coverage less expensive than you might expect. Work with an insurance advisor experienced in impaired-risk underwriting to identify carriers with current PWS-specific underwriting guidelines.

The survivorship life insurance model — in which the policy pays out at the death of the second parent — remains the most cost-effective funding mechanism for third-party SNTs. Both parents are insured under a single policy, and premiums are typically 20–40% lower than two individual policies. The SNT is named as beneficiary on the policy. See the Life Insurance for Special Needs Trusts guide for policy structure and ownership details.

Trustee selection: the PWS-specific considerations

The trustee of a PWS SNT carries responsibilities that go beyond standard SNT administration. Because cash cannot be distributed to the beneficiary and all distributions must be vendor-direct, trustee selection must include assessment of:

• Administrative capacity for vendor-direct payments: Every distribution requires the trustee to identify the appropriate vendor, confirm the expense is supplemental (not replacing a government benefit), and pay the vendor directly. Corporate trustees at large financial institutions have the administrative infrastructure to do this; individual family trustees may struggle with the volume of small vendor-direct transactions required for day-to-day PWS support.
• Understanding of PWS behavioral dynamics: A trustee who does not understand hyperphagia may be persuaded by a PWS beneficiary's insistent requests for cash or food-related gifts. Professional trustees with special needs experience will maintain the distribution protocol regardless of beneficiary pressure; well-meaning family members may not.
• Coordination with the residential provider: The trustee must work closely with the PWS residential provider to understand what the provider covers (under waiver or private pay) and what supplemental expenses remain for the SNT. This coordination requires ongoing communication — not just annual trust administration.

The co-trustee model — a family member who brings knowledge of the beneficiary paired with a professional corporate trustee who manages administration and vendor payments — is often appropriate for PWS trusts where families want involvement but recognize the administrative and behavioral management demands. See the SNT Trustee Selection guide for the full co-trustee and trust protector framework.

Priority actions for PWS families

1. Apply for the HCBS DD waiver immediately — do not wait until adulthood. Apply as soon as your child with PWS is diagnosed and old enough to be eligible (typically age 3–5 in most states). Waiver waitlists of 5–15 years mean an application today establishes a position for adulthood. The waiver funding will transform the SNT math — the difference between funded and unfunded residential care is $50,000–$100,000/year.
2. Draft or update the SNT with PWS-specific cash prohibition language. If you have an existing SNT drafted by a general estate attorney, have a special needs attorney review the distribution provisions. Standard SNT language that allows "reasonable cash distributions for personal spending" is not appropriate for a PWS beneficiary. Add vendor-direct requirements and food-access restrictions explicitly.
3. Size your life insurance for an extended planning horizon. Do not use the life expectancy statistics from 15 years ago. Adults with PWS in structured settings increasingly live into their 50s and 60s. Model the survivorship policy around a 40–50 year post-parental-death horizon, and review coverage every 5–7 years as actuarial assumptions evolve.
4. Research specialized PWS residential settings in your state before you need them. Placement waiting lists for PWS-specific group homes can be 2–5 years in many states, separate from the HCBS waiver waitlist. Identify 2–3 providers in your area now, understand their waiting lists, and, if appropriate, put your family on a placement waitlist before transition is urgent.
5. Plan for adult growth hormone coverage continuity. If your child with PWS is on pediatric GH therapy, build a plan for continuing coverage at adulthood. Work with the endocrinologist to document adult GH deficiency before the transition to adult services. Confirm coverage under the adult Medicaid plan. Budget for gap periods in the SNT if coverage is uncertain.
6. Design the ABLE account for authorized-individual management, not independent beneficiary access. If your PWS family member has significant hyperphagia, structure any ABLE account so that an authorized individual (parent, guardian) controls all disbursements. Do not provide the PWS adult with an independent ABLE debit card unless their hyperphagia is managed and there is appropriate supervision.
7. Update all beneficiary designations to route through the SNT. Every retirement account, life insurance policy, and transfer-on-death designation must name the SNT as beneficiary — not the individual with PWS. A direct inheritance of more than $2,000 instantly ends SSI and Medicaid. See the Retirement Accounts and Special Needs guide for the SECURE Act disabled exception beneficiary rules that allow lifetime IRA stretch through a properly structured SNT.
8. Work with a fee-only special needs financial planner who has PWS-specific experience. The combination of hyperphagia management, specialized housing math, SNT distribution design, and extended life expectancy planning requires a planner who has worked with PWS families before. A generalist — even a good one — will not know to ask about HCBS waiver waitlist status, vendor-direct distribution language, or GLP-1 cost planning. A specialist will.

Sources

1. Prader-Willi Syndrome Association USA (PWSA USA) — What is PWS? PWS affects approximately 1 in 10,000 to 1 in 30,000 births; commonly cited prevalence is 1 in 15,000. Approximately 20,000 to 40,000 individuals in the United States have PWS. PWS is caused by loss of normally active genes in chromosome 15q11-q13 — via paternal deletion (65–75% of cases), maternal uniparental disomy (20–30%), or an imprinting defect (1–3%). Life expectancy has improved significantly with food management; adults in structured, food-secured settings increasingly live into their 50s and 60s. PWS is one of the leading genetic causes of life-threatening childhood obesity. PWSA USA is the leading patient advocacy organization in the United States.
2. Foundation for Prader-Willi Research (FPWR) — Clinical Overview. Hyperphagia in PWS is caused by hypothalamic dysfunction — the satiety signal does not function, resulting in insatiable hunger regardless of caloric intake. Food-seeking behaviors include foraging, hoarding, eating non-food items (pica), and extreme distress when food access is restricted. Growth hormone deficiency is universal in PWS; FDA-approved GH therapy improves height, body composition, and metabolic function. Adult GH therapy may be prescribed off-label for metabolic benefits in adults with confirmed GH deficiency via stimulation testing. Skin picking (excoriation disorder) is present in 80–90% of PWS adults and may require behavioral intervention. Emerging research on GLP-1 receptor agonists (semaglutide, liraglutide) shows preliminary signals for hyperphagia reduction in clinical trials 2023–2025; not FDA-approved for hyperphagia treatment in PWS as of 2026.
3. SSA Blue Book — 12.00 Mental Disorders, Adult (Listings 12.05, 12.11). Listing 12.05 (Intellectual Disorder): requires full-scale IQ ≤70 OR full-scale IQ 71–75 with marked limitation in one area of mental functioning, AND evidence disorder began before age 22. Listing 12.11 (Neurodevelopmental Disorders): covers conditions manifesting during developmental period with deficits in cognitive, motor, language, or social domains, requiring extreme limitation in one area or marked limitation in two areas. PWS adults may qualify under 12.05 (cognitive pathway), 12.11 (neurodevelopmental pathway), 12.06 (anxiety/OCD for severe behavioral presentation), or a combination. PWS is not currently on the SSA Compassionate Allowances list as of 2026 — applications processed through standard Blue Book review. 2026 SSI FBR: $994/month; SSI resource limit: $2,000. SGA: $1,690/month non-blind; $2,830/month blind.
4. SSA Emergency Message EM-24048 — Removal of Food from In-Kind Support and Maintenance (ISM) Calculation. Effective September 30, 2024 (implemented pursuant to 20 CFR § 416.1102, 416.1130–416.1148 revisions): food provided by a third party — including via SNT distributions — no longer counts as In-Kind Support and Maintenance for SSI calculation purposes. Only shelter remains in ISM calculation. Prior to this change, food provided in-kind could reduce SSI by up to one-third of the FBR plus $20 (the Presumed Maximum Value). Post-change, SNT trustees may pay for food-related services (supervised meal programs, nutrition counseling, food delivery via licensed providers) without triggering any SSI reduction. 2026 SSI FBR: $994/month; 2026 PMV shelter cap (remaining ISM): approximately $331/month.
5. Kaiser Family Foundation — Medicaid HCBS Enrollment and Waitlists. More than 607,000 individuals with ID/DD are on HCBS Medicaid waiver waiting lists nationally. Average waitlist times vary widely by state — commonly 5–15 years for DD waivers in states with high demand. Some states have closed DD waiver waitlists entirely; others maintain waiting lists that exceed 10–15 years in some programs. Expedited waiver processing is available in most states for individuals who are medically fragile, at imminent risk of institutionalization, or experiencing a care crisis. Early application — as young as age 3–5 in most states — establishes waitlist position for adulthood transition. PWS adults typically qualify for DD waiver services based on intellectual disability or developmental disability diagnosis.
6. ABLE National Resource Center — 2026 Contribution Limits and Eligibility. Annual ABLE contribution limit: $20,000 from all sources (2026). ABLE-to-Work: working beneficiaries may contribute additional amount up to federal poverty level for one-person household ($15,650 in 2026) from earned income. Age eligibility: disability onset before age 46, effective January 2026 (ABLE Age Adjustment Act). SSI protection: ABLE account balance up to $100,000 does not count toward SSI's $2,000 resource limit; balance above $100,000 reduces SSI payment dollar-for-dollar but does not terminate eligibility. Authorized individual: ABLE accounts may be managed by an authorized individual (parent, guardian, or other designated person) who controls transactions on behalf of the account holder — this mechanism is available to protect against unsupervised spending for account holders with significant behavioral or cognitive limitations. Qualified disability expenses include health and wellness, transportation, assistive technology, housing, education, employment training, and financial management. Medicaid payback applies at beneficiary's death.

Rules verified against 2026 SSA, CMS, and ABLE standards. SSI FBR $994/month; SSI resource limit $2,000 (2026). SSDI SGA $1,690/month non-blind (2026). ABLE contribution limit $20,000/year; ABLE-to-Work additional $15,650/year; age eligibility onset before 46 (all 2026). ISM food rule change: effective September 30, 2024 (SSA EM-24048) — food no longer counted as ISM in SSI calculation. PWS prevalence: approximately 1 in 15,000 live births; 20,000–40,000 individuals in the United States. GLP-1 agonists for PWS hyperphagia: in clinical trials as of 2026; not FDA-approved for this indication. Growth hormone therapy: FDA-approved for pediatric PWS; adult coverage varies by plan and indication. This guide does not constitute financial, legal, tax, or insurance advice.